Obesity-Related Hypogonadism: The Definitive Guide

What is obesity-related hypogonadism?

Obesity-related hypogonadism is low testosterone caused mainly by excess body fat. Hormones and inflammatory signals from fat tissue turn down the signal the brain sends to the testes, and high insulin lowers SHBG, the protein that carries testosterone in the blood, so levels fall even though the testes are healthy. It often improves when weight comes down. [4], [16], [17]

Hypogonadism means the testes are not making enough testosterone. Here the problem starts above the testes: the pituitary gland sends out normal or low amounts of LH and FSH, the hormones that tell the testes to work. That pattern is secondary hypogonadism, called functional when no disease of the pituitary or testes is found; the Endocrine Society lists obesity among functional causes that "might be reversible by treating the underlying condition". [3], [9]

Other names for it are functional hypogonadism, male obesity-associated secondary hypogonadism (MOSH) and non-gonadal illness. None is a separate disease with its own cut-off: the Endocrine Society calls "functional" hypogonadism "hard to define operationally", and US medical coding records it as testicular hypofunction (E29.1) alongside an obesity code. [9], [4], [11], [16], [10], [18]

How common is low testosterone in men with obesity?

Common, but the number depends on how it is measured.

• One total testosterone test. In the US HIM study of 2,162 men aged 45 and older in primary care, 52.4% of men with obesity had a single total testosterone under 300 ng/dL (odds ratio 2.38 against men without obesity); a national survey of 10,357 men found similar odds (2.69). One test overstates true deficiency. [1], [19]
• Free testosterone. Measured the more accurate way, 40% of men with obesity and without diabetes and 50% of men with both obesity and diabetes had low free testosterone, against 26% of lean men without diabetes. [20]
• The secondary type. In the European Male Ageing Study (EMAS) of 3,369 men aged 40–79, 11.8% had secondary hypogonadism, and a BMI of 30 or more went with a relative risk ratio of 8.74 for it; age was linked mainly with the primary type (a problem in the testes themselves). Men with a BMI of 30 or more had total testosterone about 5.09 nmol/L (147 ng/dL) lower than men with a BMI under 25. [2], [21]

The Endocrine Society's patient page puts it at 30–50% of men with obesity or type 2 diabetes; how many have the full diagnosis (symptoms and repeatedly low levels) is not well measured. [22]

Is it the same as low testosterone from ageing?

No, although the two overlap. Total testosterone fell about 1.6% a year in the same men in a US study, with obesity among the factors linked with lower levels, and the European Association of Urology calls the role of ageing up to 80 "relatively small" next to obesity and other illness. The late-onset hypogonadism guide covers age-related low testosterone. [23], [4]

How is obesity-related hypogonadism diagnosed?

The same way as any low testosterone: symptoms plus at least two low early-morning blood tests. What changes with obesity is that total testosterone alone can mislead, so guidelines add SHBG, free testosterone, and LH and FSH to find the type and the cause. [3], [4], [9]

The symptoms most closely tied to low testosterone are sexual: low sex drive, fewer morning erections and erectile dysfunction. Tiredness, low mood and poor sleep are common too, but they have many other causes, including obesity itself and sleep apnea, so on their own they do not point to low testosterone. [16], [24]

Who should get their testosterone checked?

• Test men with obesity. The American Urological Association (AUA) says men with a BMI of 30 or more or a waist over 40 inches should have their testosterone checked, noting that obese men were almost five times more likely to have low testosterone (odds ratio 4.89), and the American Association of Clinical Endocrinologists (AACE) says all men with obesity or a large waist should be assessed for hypogonadism and tested if indicated. [25], [26]
• Test only when something suggests it. The European Society of Endocrinology's 2020 obesity guideline recommends testing for male hypogonadism only when there is clinical suspicion, and the Endocrine Society's 2026 statement finds no support for screening men without symptoms. [27], [10]

What testosterone level counts as low?

This table shows the line each major clinical guideline uses and what it says about obesity, checked September 2026. There is no obesity-specific cut-off: the numbers are the same for every man.

[25], [3], [10], [28], [4], [9], [29], [11], [16], [17], [30], [31]

Every body wants symptoms plus repeated low morning tests. North American bodies draw the line at about 264–300 ng/dL (9.2–10.4 nmol/L), most European bodies at 12 nmol/L (about 350 ng/dL), and the UK Society for Endocrinology uses bands. What is specific to obesity is broad agreement that SHBG or free testosterone should be checked and that weight loss comes first. Australia's subsidy rule excludes low testosterone caused by obesity (see the legal section). [3], [4], [16], [15]

Doserly

Where guidelines draw the line for low testosterone

Total testosterone below which each body supports a diagnosis, with symptoms.

Each line runs from 200 ng/dL (7 nmol/L, left) to 400 ng/dL (14 nmol/L, right); the shaded part is 264–350 ng/dL, where the guidelines' lines fall. A dashed circle means an approximate line.

Endocrine Society (2018)

Below 264 ng/dL (9.2 nmol/L), standardized assays

CUA (Canada, 2021)

Below 10 nmol/L (about 290 ng/dL)

AUA (US, 2018, reconfirmed 2024)

Below 300 ng/dL (10.4 nmol/L)

Endocrine Society statement (July 2026)

“Near 300 ng/dL”

EAU · ICSM · BSSM (Europe 2026 · international 2024 · UK 2023)

Below 12 nmol/L (about 350 ng/dL)

Every guideline also requires symptoms, and all but the CUA call for at least two morning tests; none diagnoses from a number alone.

Why can total testosterone look low when free testosterone is normal?

Because obesity lowers SHBG. About 98% of testosterone in the blood is bound to proteins (about 44% to SHBG and 50% to albumin) and about 2% is free. When SHBG falls, total testosterone falls with it, but the free, active part can stay normal. The UK Society for Endocrinology puts the low SHBG down to high insulin, which slows the liver's production of it. [25], [16], [32]

The effect is large. In 3,671 men referred for testing, each extra point of BMI went with SHBG about 1.26 nmol/L lower; men with obesity had lower total testosterone than men without (10.5 against 14.1 nmol/L, about 303 against 407 ng/dL) but the same calculated free testosterone. [5]

Doserly

Same free testosterone, different totals

Averages in 3,671 men tested for low testosterone: without obesity vs with obesity (BMI above 30).

Grey bar: men without obesity. Teal bar: men with obesity. Each measure has its own scale.

SHBG (the carrier protein)

Without obesity

50 nmol/L

With obesity

36 nmol/L

Total testosterone (what most tests report)

Without obesity

14.1 nmol/L (about 407 ng/dL)

With obesity

10.5 nmol/L (about 303 ng/dL)

Calculated free testosterone (what the body can use)

Without and with obesity

No difference (the study published no values)

Low SHBG pulls total testosterone down while free testosterone stays the same, so men with obesity need SHBG or free testosterone checked. Records study; group averages, not a personal result.

It matters for symptoms too. In EMAS, 4.9% of men developed low total testosterone with normal free testosterone over 4.3 years, and 1.9% developed low total and low free testosterone; only the second group developed new sexual symptoms. [24] In 35 severely obese men, 25 met the definition by total testosterone but only 16 by free testosterone. [33]

So guidelines ask for free testosterone or SHBG in men with obesity, measured by equilibrium dialysis or calculated from total testosterone, SHBG and albumin, not by the direct free-testosterone kits the Endocrine Society advises against. [3], [11] They differ on how much weight to give it: the EAU, EAA, BSSM, VA and SIAMS use free testosterone when SHBG is altered (those that give a number put it at 220–225 pmol/L), while the AUA does not make it the primary test and the Endocrine Society of Australia does not recommend calculated free testosterone for decisions. [4], [9], [28], [31], [25], [30]

The testosterone unit and free T converter switches between ng/dL and nmol/L and estimates free testosterone from total testosterone, SHBG and albumin.

What other tests look for a cause?

LH and FSH come first. In men with obesity they are usually low or normal, which fits the secondary type; high levels point to a problem in the testes. Doctors then look for other causes before putting it down to weight: [3], [21], [34]

• Prolactin, when LH is low or low-normal, and a pituitary scan (MRI) when testosterone is very low: the AUA uses under 150 ng/dL with low or low-normal LH, the EAU under 6 nmol/L. [25], [4]
• Iron studies, because iron overload (hemochromatosis) is a treatable cause. [3], [17]
• Medicines: opioid painkillers and steroid tablets (glucocorticoids) lower testosterone; the Canadian Urological Association lists obesity, opioids, glucocorticoids and sleep apnea among causes to treat before rechecking. [17], [10]
• Blood sugar: the AUA suggests checking HbA1c in men with obesity or metabolic syndrome. [25]
• Biotin: the supplement can throw off LH and FSH tests; the Endocrine Society advises stopping it for at least 72 hours first. [3]

How should the blood test be done?

Early in the morning, fasting, and more than once; the time windows in the table differ by an hour or two between guidelines. Weight change matters for interpretation: the Endocrine Society of Australia says testosterone that stays low despite successful weight loss should prompt reassessment, in case a pathological cause was missed. We found no study of testosterone during rapid weight loss in men with obesity, so whether a steep calorie deficit itself lowers the reading is not settled (see what people report). [30]

What causes obesity-related hypogonadism?

Several things at once, and they feed each other; guidelines list them without singling out one main cause, and the Canadian and UK guidelines call the link two-way because low testosterone also makes it easier to gain fat. [16], [17], [4]

• Less SHBG (human studies). Higher fasting insulin went with lower SHBG in a population survey of men, and lower SHBG means lower total testosterone (see above). [32], [16]
• A weaker brain signal (human studies). In EMAS, the lower testosterone that came with obesity came with unchanged or lower LH: the testes get less of a push. [21], [34]
• Estrogen feedback (human trials, with a conflict). Fat tissue contains aromatase, the enzyme that turns testosterone into estradiol, and estradiol tells the brain to cut LH. Blocking aromatase with letrozole in a 6-month trial of 42 men with obesity raised total testosterone from 8.6 to 21.5 nmol/L (248 to 620 ng/dL), so estrogen feedback plays a part. But tissue studies conflict: one found no difference in fat aromatase between obese and normal-weight men, and another found more, with no link to blood estradiol. [35], [36], [37]
• Leptin (human association; animal studies). In men from normal weight to very obese, leptin, a hormone made by fat cells, was the best hormonal predictor of lower testosterone, and obese men's testes made 30–40% less testosterone when stimulated; rodent studies suggest a direct effect on the testes. A proposed effect on kisspeptin, a brain signal upstream of LH, has not been shown in men. [38]
• Inflammation (human experiment). An infusion of one inflammatory messenger (interleukin-2) reduced LH-driven testosterone output in 35 healthy men, not men with obesity. [39], [4]
• The reverse direction (human trial). When 400 healthy men had their own hormones switched off and were given set amounts back, body fat rose at the lower testosterone doses, and the loss of estradiol, more than of testosterone, explained the fat gain. [40]

Weight change moves testosterone in the same men. In 2,395 EMAS men followed for 4.4 years, losing weight raised total testosterone and SHBG and gaining weight lowered them; free testosterone changed significantly only with a weight change of 15% or more. Of the men who developed secondary hypogonadism, 42.9% recovered to normal levels, more often if they were not obese or lost weight (odds ratio 2.24), although their symptoms did not improve at the same time. [41], [42] Type 2 diabetes adds to the effect: a third of 103 men with type 2 diabetes had low free testosterone, with LH and FSH low or normal rather than high (the secondary type). [34]

What role does sleep apnea play?

It travels with obesity, but weight seems to matter more than the apnea itself. In 623 Australian community men (average BMI 28.6), 51.5% had sleep apnea; its link with lower testosterone disappeared once age, BMI and SHBG were taken into account. The Endocrine Society of Australia says low testosterone levels in men with obstructive sleep apnea "are related primarily to obesity and will improve with weight loss". [43], [44]

Does treating sleep apnea raise testosterone? Mostly no. CPAP (a machine that keeps the airway open with air pressure) did not significantly change total testosterone in a 2019 pooled analysis of 12 studies (a change of 1.08 nmol/L, too uncertain to count) or a 2014 analysis of 7 studies. A 1-month trial against sham CPAP in 101 men found only a rise in SHBG, and a 3-month study in 27 men found no change; one 2026 study of 14 men with severe obesity saw a rise, without a comparison group. Treat sleep apnea for its own sake, not to fix testosterone. [45], [46], [47], [48], [49]

Weight loss treats both. The AACE obesity guideline sets a weight-loss goal of at least 7–11% for sleep apnea, and tirzepatide (Zepbound) is approved in the US to treat moderate to severe obstructive sleep apnea in adults with obesity, alongside diet and exercise (checked September 2026). [26], [50]

What is estrogen doing?

Estradiol matters in the feedback loop, but routine estrogen testing and estrogen-blocking tablets are not part of guideline care. Weight loss lowers estradiol and raises LH and FSH, according to a pooled analysis of weight-loss studies, and the AUA measures estradiol before treatment only in men with breast symptoms or breast enlargement. Raising testosterone by blocking estrogen did not make men with obesity feel better (see aromatase inhibitors). The estrogen on TRT guide covers estradiol in detail. [7], [25], [35]

How is obesity-related hypogonadism usually treated?

By treating the weight first in most guidelines, with testosterone therapy (TRT) for men who have confirmed low testosterone, clear symptoms and no plans for children soon. This section describes the choices clinicians weigh; it is not a personal plan. [4], [9], [10], [25]

[4], [9], [10], [25], [6], [7], [51], [52], [53], [29], [8], [54], [11], [55], [56], [57], [28], [35], [45]

Should you lose weight first or start TRT?

Most guidelines say weight first, but one major guideline disagrees, and none sets a fixed waiting time.

• Weight loss first. The EAU strongly recommends improving lifestyle and reducing weight before starting testosterone. The EAA recommends lifestyle change and weight loss for overweight men with functional hypogonadism, the Endocrine Society's 2026 statement calls weight loss "typically the first-line therapy" when obesity (a BMI over 27) is the only cause, a 2026 Brazilian joint position statement strongly recommends it as first-line, and the UK Society for Endocrinology calls lifestyle change, weight loss and treating sleep apnea the "mainstays of management". [4], [9], [10], [58], [16]
• Both together. The BSSM says current evidence "does not support the recommendation for lifestyle intervention alone as first-line therapy" and endorses lifestyle change together with testosterone in men with symptoms. The AUA counsels every man with low testosterone on lifestyle change and advises weight-loss programs alongside testosterone for men who are overweight. The Canadian guideline says lifestyle change may help, on weak evidence, and a 2024 review argues that because weight loss is hard to reach in practice, testosterone is often needed. [11], [25], [17], [59]

The disagreement comes down to two facts: weight loss raises testosterone less than many men hope unless the loss is large, and it is hard to keep off (the EAU notes that 60–86% of lost weight is regained within three years); and in EMAS, men whose testosterone recovered did not report better symptoms at the same time. A 2026 network meta-analysis of 23 trials (1,899 men with obesity) found testosterone plus a structured lifestyle program raised testosterone the most, but no single strategy was consistently better, with low or very low confidence in many comparisons. [4], [42], [60]

How much does losing weight raise testosterone?

On average, a few nmol/L with diet and much more with surgery.

[7], [6], [30], [4], [61]

Doserly

How much testosterone rises with weight loss

Average rise in total testosterone, by kind of weight loss (pooled analyses and guidelines).

Each line runs from 0 (left) to +10 nmol/L (right), about +288 ng/dL. A band is a range given by the source; a dot is a pooled average.

Diet and lifestyle

Diet and activity (EAU 2026)

+1–2 nmol/L (29–58 ng/dL)

10% weight loss (ESA 2016)

+2–3 nmol/L (58–87 ng/dL)

Pooled 2024 (44 studies): diet

+2.5 nmol/L (about 72 ng/dL)

Pooled 2013 (24 studies): diet

+2.87 nmol/L (about 83 ng/dL)

Weight-loss medicines

GLP-1 medicines and tirzepatide, small studies (2026 review)

+2.5–5.2 nmol/L (72–150 ng/dL)

Surgery

Pooled 2024: bariatric surgery

+7.2 nmol/L (about 208 ng/dL)

Pooled 2013: bariatric surgery

+8.73 nmol/L (about 252 ng/dL)

Diet-based weight loss adds a few nmol/L on average; bariatric surgery adds more. Group averages from different studies and men, not a prediction for one person; GLP-1 medicines are not approved for low testosterone.

Bigger losses gave bigger rises, and so did starting heavier. On age the two pooled analyses differ: the 2013 analysis found larger rises in younger men without diabetes, while the 2024 analysis found total testosterone rose relatively more in older men and free testosterone more in younger men. The AACE says a weight loss of more than 5–10% is needed for a meaningful rise. [7], [6], [26] Individual trials fit: the type of diet made no difference in 118 men over 52 weeks; a 10.1 kg diet weight loss raised total testosterone by 71.0 ng/dL (about 2.5 nmol/L) in frail older men; 200–300 minutes a week of exercise raised it by 2.06 against 0.79 nmol/L with under 150 minutes, but with twice the weight loss; and in the Look AHEAD study of 890 men with type 2 diabetes, an intensive lifestyle program raised it by 14% at one year, an effect that faded over four years. [62], [63], [64], [65]

Does the rise last? It holds if the weight stays off: after a 9-week very-low-calorie diet in 58 men, free testosterone stayed up through a year of weight maintenance (185 to 208 to 212 pmol/L). No controlled study has tested whether it falls again when weight is regained. [66]

Is it true that every 10 lb lost adds 100 ng/dL? No study supports a rule like that; a 10% weight loss adds about 2–3 nmol/L (58–87 ng/dL) on average. [30]

Can bariatric surgery fix low testosterone?

For many men, yes, at least for the hormones. Current US and international surgical society criteria (2022) recommend weight-loss surgery at a BMI of 35 or more, whatever other conditions a person has, and suggest considering it at 30–34.9 with metabolic disease. They replace the older cut-offs of 40, or 35 with other illness, that are still widely quoted. [52]

• How often it normalizes. Of 29 very obese men, 22 (75.9%) had low total or free testosterone before surgery; 6 months after surgery, 22 of the 29 had normal total and calculated free testosterone (7 had normal levels to begin with). In 35 men, low testosterone (present in 25 by total testosterone) resolved after surgery in all but one. [67], [33]
• How long it lasts. In a randomized trial of 32 men with type 2 diabetes, free testosterone was 47.4% higher 5 years after surgery, against a 2.2% fall with medical treatment; in another 32 men, total testosterone and SHBG were still higher at year 4. [68], [69]
• Sperm. A pooled analysis found surgery "did not affect sperm quality", and in the BARIASPERM study of 46 men, total sperm count fell by 69.5 million 12 months after surgery. We found no guideline that sets a waiting period before trying for children. [53], [70]

Do semaglutide and tirzepatide raise testosterone?

Yes, in small studies, mostly through weight loss, but they are not approved as a treatment for low testosterone. GLP-1 medicines such as semaglutide (Wegovy, usually 2.4 mg once a week by injection or 25 mg once a day as a tablet) and tirzepatide (Zepbound) are approved in the US for weight management, and their labels have no hypogonadism indication (checked September 2026). [71], [50]

• The size of the rise. A 2026 review of small, short studies found GLP-1 medicines and tirzepatide raised total testosterone by about 2.5–5.2 nmol/L in men with obesity-related low testosterone. In a records study of 215 men without a comparison group, about 5% weight loss was followed by a rise from 332 to 399 ng/dL on average, and the share with normal testosterone rose from 67% to 86%. [8], [72]
• Against testosterone gel. In a 16-week trial of 30 men with obesity and low testosterone, liraglutide raised testosterone by 2.6 nmol/L with 7.9 kg of weight loss, while testosterone gel raised it by 5.9 nmol/L with 0.9 kg. Both improved sexual function. [73]
• The body's own system keeps working. A 2026 review of 10 studies (639 men) found GLP-1 medicines raised total testosterone while keeping LH and FSH working, unlike testosterone therapy, though free testosterone changes were inconsistent; one pooled analysis found no significant change in free testosterone at all. In 25 men with obesity and type 2 diabetes, normally shaped sperm rose from 2% to 4% on semaglutide, while sperm counts fell on testosterone. [54], [74], [75], [76]
• With testosterone. Evidence for combining a GLP-1 medicine with testosterone is thin: a 10-man pilot in men who lost little weight on tirzepatide, and a 93-man single-clinic series with no comparison group in which lean mass still fell 4.0–6.1 kg over a year of tirzepatide, testosterone and exercise coaching. [77], [78]

Only the ICSM 2024 panel mentions them, as a "possible role". The TRT with GLP-1 medicines guide covers using both together. [29]

Are clomiphene, enclomiphene or aromatase inhibitors an option?

They raise testosterone by boosting the body's own LH, which works only when the brain-to-testes system is intact, as it is here. They are off-label in men and the evidence is thin. [4]

• Clomiphene and enclomiphene (SERMs, tablets that block estrogen's brake on the brain). In a pooled analysis of 7 studies of 292 men with obesity, clomiphene raised total testosterone by 11.56 nmol/L and enclomiphene by 7.50 nmol/L over 1.5–4 months. In randomized trials, clomiphene 50 mg raised testosterone, LH and FSH in 78 men with obesity but lowered HDL ("good") cholesterol, and 25 mg a day raised testosterone from about 303 to 599 ng/dL (10.5 to 20.8 nmol/L) in 21 men taking metformin. In two phase 3 trials in overweight men, enclomiphene kept sperm counts normal while AndroGel 1.62% lowered them sharply. [56], [79], [80], [81]
• Their limits. The Endocrine Society notes clomiphene's efficacy and safety have not been shown in randomized trials of hypogonadism, the EAU calls the evidence poor and warns of a possible blood-clot risk, and the EU refused to approve enclomiphene in 2018 over unproven symptom benefit and a clot risk. See the clomiphene and enclomiphene guides. [3], [4], [57]
• Aromatase inhibitors (letrozole, anastrozole). They raised testosterone in men with obesity, from 7.5 to 23.8 nmol/L (216 to 686 ng/dL) in 6 weeks in a 10-man pilot and above the normal range for free testosterone in 7 of 12 men in another, but the two randomized trials found no benefit in how men felt, and a year of anastrozole in older men lowered spine bone density. The VA does not generally recommend them. See the anastrozole guide. [82], [83], [35], [84], [85], [28]

What does testosterone therapy involve?

The same medicines and monitoring as for any man with low testosterone. Testosterone comes as injections (cypionate, enanthate and the long-acting undecanoate injection), gels, oral capsules, nasal gel and pellets. [25]

Guidelines aim for the middle of the normal range (the AUA targets 450–600 ng/dL, or 15.6–20.8 nmol/L) and check testosterone and hematocrit at 3–6 months, at 12 months and then yearly. The EAU suggests starting with a gel rather than a long-acting injection in men at higher risk, and it lists severe obesity among the risks for a high red-cell count. SHBG rises as weight comes off, which moves total testosterone readings, so results are best read with SHBG alongside. The TRT dosage guide covers doses, and the TRT dose calculator turns a prescribed dose into mL and syringe units. Testosterone for women uses different products and doses; see testosterone therapy for women. [25], [3], [4], [66]

What if you want children?

Then testosterone therapy is the wrong choice for now, and weight loss is on your side.

• Obesity itself lowers sperm counts. In a pooled analysis of 21 studies (13,077 men), the odds of a very low or absent sperm count were 1.28 times higher with obesity and 2.04 times higher with severe obesity than at a normal weight. Losing an average of 16.5 kg on a low-calorie diet raised sperm concentration 1.49-fold, and only the men who kept the weight off kept the gain. [86], [51]
• Testosterone can switch sperm production off. Outside testosterone lowers the LH and FSH the testes need to make sperm, and labels warn that reduced fertility may not be reversible in some men. The AUA says testosterone should not be prescribed to men trying to conceive. After stopping, sperm counts in contraceptive studies recovered in 67% of men within 6 months and in all within 24 months. [55], [25], [87]
• Options that keep sperm production going include weight loss, GLP-1 medicines (which keep LH and FSH working), clomiphene or enclomiphene, and hCG. See TRT and fertility and hCG vs gonadorelin vs enclomiphene. [54], [81], [25]

Can you stop TRT after losing weight?

Sometimes, and guidelines allow for trying. The EAA says testosterone "withdrawal may be considered following weight reduction", and the VA says significant weight change may prompt an earlier testosterone check. [9], [28]

Expect it to take time. After two years of long-acting injections in the T4DM trial, men's own LH and FSH recovered slowly over 12 months, and full recovery may take longer; in a survey of 599 of those men (316 former testosterone users, 283 former placebo users) about five years after the last injection, 6% of the former testosterone users had restarted testosterone, against 2.8% of the former placebo users. In men with obesity who had testosterone during a weight-loss program, the extra fat loss and lean-mass protection were gone about 82 weeks after stopping. [88], [89], [90]

Stopping is a decision to plan with your prescriber, with repeat blood tests; the stopping TRT guide covers what happens and when.

What does testosterone therapy do for men with obesity?

It improves some symptoms and body composition, but it does not reliably cause weight loss, and its effect on blood sugar depends on the trial. [91], [60]

Will testosterone therapy help you lose weight?

Not on the scale, in the trials. Across 29 randomized trials in middle-aged and older men, testosterone reduced fat by about 1.6 kg and added about 1.6 kg of fat-free mass without changing body weight, and in the diet trial above both groups lost the same weight (12.0 against 13.5 kg after the diet). [100], [94], [93]

Guidelines split on how to describe this:

• Against using it for weight. The EAA recommends against testosterone "as a treatment for weight reduction in obese men", the EAU advises not using it to reduce weight or improve heart and metabolic health, the 2026 Brazilian statement does not recommend it for weight loss alone, and the Canadian obesity guideline found "insufficient evidence" for testosterone as an obesity treatment. [9], [4], [58], [101]
• More positive. The AACE's 2016 obesity guideline says testosterone in men with true hypogonadism and obesity "results in weight loss, decreased waist circumference, and improvements in metabolic parameters" (its strongest grade). [26]

The big weight losses you may see quoted come from long-term registries, not trials: in one of 411 men followed for up to 8 years, men with class I obesity went from 102.6 to 84.1 kg on testosterone. These registries had no comparison group, overlap with each other and had authors employed or paid by the testosterone maker, so they cannot show that testosterone caused the weight loss. [102], [103], [104], [105]

Does testosterone therapy help blood sugar?

Only in one large trial, and only alongside a lifestyle program. In T4DM, testosterone plus lifestyle lowered new diabetes at 2 years (12%, 55 of 443, against 21%, 87 of 413), and loss of fat mass explained much of that. In the TRAVERSE trial, which had no structured lifestyle program, testosterone gel did not significantly reduce progression from prediabetes to diabetes (for example 7.8%, 45 of 575, against 10.7%, 57 of 533, at 12 months), and the smaller trials above gave mixed results. [12], [92], [106], [95], [97], [96], [99]

The guidelines split the same way. The Endocrine Society and the EAA recommend against testosterone to improve blood sugar, and the American Diabetes Association does not recommend it to prevent type 2 diabetes. The Italian SIAMS guideline suggests it for men with hypogonadism and metabolic syndrome or prediabetes, and the BSSM treats symptomatic prediabetes when total testosterone is under 14 nmol/L (404 ng/dL). [3], [9], [107], [31], [11]

Does it improve symptoms in men with obesity?

Some, mostly sexual. In pooled data from trials in men with testosterone under 12 nmol/L (about 350 ng/dL), erectile function scores rose by about 2 points whatever the men's weight or diabetes status. In T4DM, testosterone improved average scores in all five domains of a sexual-function questionnaire. A meaningful gain in sexual desire came to 32% of men on testosterone (131 of 430) against 22% on placebo (85 of 395), a significant difference; for erectile function it was 23% against 20%, which was not significant. The weight lost through the lifestyle program improved more quality-of-life measures than testosterone did. In the diet trial, testosterone improved symptom scores by 11% to 20% from starting scores of 40 to 60. [108], [109], [110], [94]

Is testosterone therapy safe for men with obesity?

It is an approved treatment with known risks, several of them more likely with obesity. The BSSM notes that obese men are more likely to have side effects than men of normal weight, and the UK Society for Endocrinology says the frequent rise in red blood cells makes the balance of benefit and risk "far less clear" in these men. [11], [16]

• Red blood cells. Testosterone raises hematocrit, the share of blood made up of red cells. In T4DM (men with a large waist), it went above 54% in 22% on testosterone (106 of 491) against 1% on placebo (6 of 484). Most guidelines act at 54%. See hematocrit on TRT. [12], [3]
• Sleep apnea. US labels warn that testosterone "may potentiate sleep apnea in some patients, especially those with risk factors such as obesity". In 67 obese men with severe sleep apnea, testosterone injections worsened night-time oxygen drops by 10.3 events an hour at 7 weeks but not at 18 weeks, and in a later survey of 599 T4DM men (316 on testosterone, 283 on placebo), 3.0% against 0.4% reported a new sleep apnea diagnosis during the trial. [13], [111], [112], [113], [89]
• Blood clots. The UK Society for Endocrinology notes that men with obesity were at higher risk of clots in veins on testosterone in an observational study, highest in the first 6 months. In TRAVERSE, clots in veins occurred in 1.7% on testosterone against 1.2% on placebo (44 of 2,596 against 30 of 2,602), a difference that could be due to chance. [16], [114]

What did TRAVERSE show about heart safety?

TRAVERSE is the largest trial of testosterone and heart safety, with about 5,200 men aged 45–80 with low testosterone and existing heart disease or high heart risk, on daily testosterone gel or placebo gel. Heart attack, stroke or cardiovascular death occurred in 7.0% on testosterone and 7.3% on placebo (182 of 2,596 against 190 of 2,602; hazard ratio 0.96), which met the trial's safety goal. Some problems were more common on testosterone: atrial fibrillation 3.5% against 2.4%, acute kidney injury 2.3% against 1.5%, pulmonary embolism 0.9% against 0.5%, and clinical fractures 3.50% against 2.46% (91 of 2,601 against 64 of 2,603). Two substudies matter for the questions above. In men with low libido, the gel raised sexual activity and desire but not erectile function. High-grade prostate cancer was rare in both groups (5 of 2,596 on testosterone, 3 of 2,602 on placebo). [115], [114], [116], [117], [118]

Its limits matter: it tested only a daily gel, men used it for an average of 21.7 months, about 61% stopped their study gel early, and no results for men with obesity specifically have been published that we could read. The TRT and heart health guide covers the trial in full. [115], [114]

Who should be especially cautious?

• Men with untreated sleep apnea. The Endocrine Society and the VA list untreated severe sleep apnea as a reason not to start. [3], [28]
• Men who want children soon (see fertility). [25]
• Men with a high hematocrit before starting. The Endocrine Society treats a baseline above 48% (above 50% at high altitude) as a reason for caution. [3]
• Men with a history of blood clots or an inherited clotting tendency (thrombophilia), a recent heart attack or stroke, uncontrolled heart failure, or breast or prostate cancer. [3], [28]
• Men taking diabetes medicines, because testosterone can lower blood sugar (see interactions). [119]
• Drug-tested athletes. Testosterone is prohibited in sport at all times. [120]
• Under-18s. Low testosterone in teenagers with obesity, including delayed puberty, belongs in specialist care.
• Women. This guide is written for men. See testosterone therapy for women.

Which medicines interact with testosterone?

• Insulin and other diabetes medicines. US labels say androgens may lower blood glucose and so reduce insulin needs, and the oral testosterone labels say this may mean lowering the dose of diabetes medicines. This matters for men also starting a GLP-1 medicine, insulin or a sulfonylurea. [119], [112]
• Blood thinners. Labels warn testosterone may increase sensitivity to oral anticoagulants such as warfarin, so clotting tests need closer checks. [119]
• SGLT2 inhibitors (empagliflozin, dapagliflozin). In US veterans with diabetes, taking an SGLT2 inhibitor with testosterone went with about 2.5 times the odds of a hematocrit above 54% compared with testosterone alone, and UK testosterone labels warn about the combination. [121], [122]
• Steroid tablets (corticosteroids). Taking them with testosterone may increase fluid retention, the labels say, and they lower the body's own testosterone. [13], [17]
• GLP-1 medicines. We found no study of a direct drug interaction with testosterone; the overlap is blood sugar.
• Opioid painkillers lower testosterone themselves; see primary vs secondary hypogonadism. [17]

Bring a complete list of what you take, including supplements, to a pharmacist or prescriber. Checked September 2026.

Is testosterone legal, and is it allowed in sport?

Checked September 2026. Rules differ by country and change often.

• United States. Testosterone and its esters are Schedule III controlled substances, prescription only. In June 2026 the FDA asked makers to change testosterone labels (for example, removing the age-related limitation); these are requests, not yet in any label. [14], [123]
• United Kingdom. Testosterone is a Class C controlled drug, in Schedule 4 Part II of the Misuse of Drugs Regulations 2001. [124], [125]
• Canada. Testosterone is a Schedule IV controlled substance. [126]
• Australia. Testosterone is a Schedule 4 prescription-only medicine. The government subsidy (PBS) for men without a pituitary or testicular disorder excludes low testosterone due to obesity, as well as age, heart disease, infertility or drugs. [127], [15]
• Sport. The World Anti-Doping Agency (WADA) prohibits testosterone at all times, and its 2027 list keeps the ban. Its guidance grants a therapeutic use exemption only for organic hypogonadism, not for functional low testosterone such as that caused by obesity. Semaglutide and tirzepatide are on WADA's monitoring program, which tracks use, not on the prohibited list. [120], [128], [129], [130]

What do people in public communities report?

Public forums are full of men with obesity weighing the same choice: keep losing weight and retest, or start testosterone now. The threads below are recent public Reddit discussions, read with their replies; they show what people experience, not how often it happens.

"My doctor says losing weight will fix it"

This is the most common starting point. One man at 190 ng/dL with low-normal LH and mild sleep apnea said his endocrinologist kept advising weight loss; an earlier TRT course had ended with erectile problems and a hematocrit of 51.3%. Another, with years of low SHBG, said two endocrinologists declined TRT because they linked his low testosterone to obesity. Others chose the weight route themselves: a man in his early 20s at 268 ng/dL who wants children decided to lose weight and retest first, and a man who had lost 63 lb on tirzepatide, with results of 308, 341 and then 277 ng/dL, planned to keep going before deciding. [131], [132], [133], [134]

What happens to testosterone after big weight loss?

Some men see large rises. One man who held off prescribed testosterone reported total testosterone of 144, 331, 455, 553 and 625 ng/dL as his weight fell from 498 to 302 lb with GLP-1 medicines; he had also had untreated sleep apnea at his heaviest. Another went from about 216–237 to 521 ng/dL after losing 93 lb on tirzepatide, with sleep apnea also treated. Others see little change: a man who lost 100 lb with diet and hard cycling stayed between about 230 and 400 ng/dL over three years of tests, with low energy and libido. [135], [136], [137]

Several posters wonder whether a hard diet lowered their reading, which research has not settled: one man tested at 4.9 nmol/L after a 30 kg loss with fasting days, then 11.0 nmol/L two months after eating at maintenance. [138] Another, who lost 60 lb in 5 months and felt worse at 9.2 nmol/L, chose to ease his calorie deficit before deciding on TRT. [139]

Do better numbers mean feeling better?

Not always. A man whose total testosterone rose from 11.9 to 21.9 nmol/L after about 8% weight loss and CPAP still felt exhausted and flat. A young man whose sleep apnea index fell from 44 to 1 on CPAP felt no benefit after six months. Another started TRT with a total testosterone of 540 ng/dL, not a low result, and reported no benefit after nine months at about 900 ng/dL, plus severe acne; he restarted CPAP and planned to focus on sleep and weight. [140], [141], [142]

What about weight and sleep on TRT?

Weight results vary. One man started TRT at 320 lb and reached 229 lb over two and a half years of lifting and running; as the weight came off, the same weekly dose pushed his level above 1,200 ng/dL and his dose was lowered. Another gained about 13–15 lb in his first five months while eating better without counting calories, though he felt stronger. [143], [144]

Worse sleep is a recurring theme. A man with long-standing sleep apnea on CPAP said his sleep and thinking got much worse on testosterone and began to clear 10 days after stopping. Another woke gasping at week 14; his doctors paused TRT until a sleep study, and he reported panic and low mood in the days after stopping. One poster who started 200 mg a week at about 350 lb described testosterone near 2,100 ng/dL, a hematocrit of 58% and sleep apnea found during treatment; the dose was lowered, and weight loss and a GLP-1 medicine followed. [145], [146], [147]

What happens with clomiphene or stopping?

Clomiphene stories mostly report bigger numbers with the cause hard to pin down: a man who wanted more children went from 252 to 723 ng/dL on 50 mg daily while his weight and thyroid tests were also changing, and another, on a weight-loss medicine, went from about 290–355 to 662 ng/dL and could not tell which change helped. [148], [149]

Few threads report what happens after stopping. A man who started TRT at 310 lb and 175 ng/dL lost about 95 lb, stopped for cost, and measured 328 ng/dL six months later with his symptoms back. [150]

How can you judge an obesity and testosterone story?

Ask: Were there at least two early-morning fasting tests? Was SHBG or free testosterone measured, and what were LH and FSH? Was the man losing weight fast at the time of the test, and on which medicines? Was sleep apnea checked and treated? Did several things change at once, such as diet, training, a weight-loss medicine and TRT? And what did the next test show? One poster asked whether every 10 lb lost adds 100 points, based on three readings; replies pointed out how much single readings vary. [151]

These selected discussions show what people experience and the questions research has not answered. They are not a survey of all men with obesity, a success rate or a substitute for the studies above.

What should you track?

Testosterone with SHBG or free testosterone, LH and FSH, and the things weight changes: waist, blood sugar and blood pressure. On testosterone therapy, hematocrit and PSA join the list. Use this to prepare questions for your clinician; it is not a personal testing plan. [4], [25], [3]

[28], [30], [3], [4], [25], [13]

Weight loss changes SHBG, total testosterone and blood sugar over months, so a series of results drawn the same way (early morning, fasting, same lab) says more than any one number. The TRT blood work guide covers when to draw each test.

Common questions about obesity-related hypogonadism

Is my low testosterone caused by my weight?

It may be. Obesity is probably the condition most often linked with low testosterone in men, but the diagnosis needs symptoms, two low morning tests, SHBG or free testosterone, and LH and FSH, plus a look for other causes such as opioids, steroid tablets or a pituitary problem. A normal free testosterone with low total testosterone points to low SHBG rather than a true deficiency. [20], [2], [3], [5] See how it is diagnosed.

Can I raise my testosterone just by losing weight?

Often, but by less than many people hope unless the weight loss is large. On average, diet-based weight loss raised total testosterone about 2.5–2.9 nmol/L and bariatric surgery about 7.2–8.7 nmol/L, and a 10% weight loss adds about 2–3 nmol/L. Whether that is enough depends on how low you started. [6], [7], [30] See how much weight loss helps.

Should I start TRT or lose weight first?

Most guidelines say weight first for obesity-related low testosterone, but the British Society for Sexual Medicine advises lifestyle change together with testosterone for men with bothersome symptoms. Fertility plans, how severe the symptoms are and how low the levels are all shift the balance; it is a decision to make with your clinician. [4], [10], [11] See weight first or TRT.

Will TRT help me lose weight?

Not on the scale, in trials. Testosterone reduces fat and adds lean mass by about the same amount, so body weight barely changes, and dieting men lost the same weight on testosterone or placebo. The European andrology guideline recommends against using it for weight loss. [100], [94], [9] See what TRT does.

Does Ozempic, Wegovy or Zepbound raise testosterone?

In small studies, yes: GLP-1 medicines and tirzepatide raised total testosterone by about 2.5–5.2 nmol/L in men with obesity-related low testosterone, mainly through weight loss, and kept LH and FSH working. Wegovy and Zepbound are approved for weight management (Zepbound also for sleep apnea with obesity), not for low testosterone. [8], [54], [71], [50] See GLP-1 medicines.

Does CPAP raise testosterone?

Usually not. Pooled studies found no significant change in testosterone with CPAP, and low testosterone in men with sleep apnea seems to follow weight rather than the apnea itself. CPAP is still worth using for the sleep apnea, which testosterone therapy can worsen. [45], [43], [13] See sleep apnea.

Can bariatric surgery cure low testosterone?

For many men the hormones return to normal: in one study of 29 very obese men, 22 had normal total and free testosterone 6 months after surgery (7 had normal levels to begin with), and pooled studies found rises of about 7.2–8.7 nmol/L. Sperm quality has not improved as reliably. [67], [6], [53] See surgery.

If I start TRT, will I be on it for life?

Not necessarily. The European andrology guideline allows stopping after weight loss, but the body's own LH and FSH can take a year or more to recover after long-term injections, and some men restart. [9], [88], [89] See stopping after weight loss.

Glossary

Plain explanations of the medical, lab and research terms used in this guide. Underlined terms in the text link here.

Aromatase

The enzyme that turns testosterone into estradiol. Fat tissue contains it, so body fat is one of the places estradiol is made in men.

BMI (body mass index)

Weight in kilograms divided by height in meters squared. A BMI of 30 or more counts as obesity in most guidelines; it does not measure where fat sits, which is why waist size is measured too.

Controlled trial

A study that compares people who receive a treatment with a similar group who do not, often receiving a placebo instead. Randomly assigning people to each group makes the comparison fairer.

CPAP

Continuous positive airway pressure: a bedside machine that blows air through a mask to keep the airway open during sleep. It is the standard treatment for obstructive sleep apnea.

Equilibrium dialysis

The reference laboratory method for measuring free testosterone directly. Calculating free testosterone from total testosterone, SHBG and albumin is the usual alternative.

Free testosterone

The small share of testosterone, about 2%, that is not bound to proteins in the blood and can act on the body. It is measured by equilibrium dialysis or calculated.

Functional hypogonadism

Low testosterone caused by something that can change, such as obesity, illness or medicines, with no disease of the pituitary or testes. It may improve when the cause is treated.

GLP-1 medicines

Weight-loss and diabetes medicines, such as semaglutide (Ozempic, Wegovy), liraglutide and tirzepatide (Mounjaro, Zepbound), that copy a gut hormone which reduces appetite. Tirzepatide also acts on a second gut hormone, GIP.

Clinical guideline

Recommendations written by a medical society or health system, based on its review of the evidence and expert judgment. Different guidelines can reach different conclusions.

Hazard ratio

A measure comparing how often something happens over time in two groups. A hazard ratio of 1 means no difference; 0.96 means about 4% fewer events in the first group.

HbA1c

A blood test that shows average blood sugar over about the last 3 months.

Hematocrit

The share of the blood made up of red blood cells. Testosterone therapy can raise it, which is why it is checked.

Hypogonadism

Symptoms of testosterone deficiency together with testosterone levels that are low on repeated morning blood tests.

LH and FSH

Luteinizing hormone and follicle-stimulating hormone, made by the pituitary gland. LH tells the testes to make testosterone; FSH, with testosterone inside the testes, drives sperm production.

Meta-analysis and systematic review

A systematic review gathers all studies on a question in a planned way. A meta-analysis combines their results statistically. A network meta-analysis compares several treatments at once, even ones never tested head to head.

Pituitary MRI

A magnetic scan of the pituitary gland at the base of the brain, used to look for a growth when testosterone is very low with low LH or prolactin is high.

Odds ratio

A measure comparing the odds of an outcome in two groups. An odds ratio of 2 means roughly twice the odds; 1 means no difference.

Placebo

A dummy treatment with no active ingredient, used as a comparison in studies.

Prolactin

A pituitary hormone. A high level can switch off LH and lower testosterone, and it can point to a pituitary growth.

Relative risk ratio

A measure of how much more likely an outcome is in one group than in another, compared with a reference outcome (here, normal testosterone). A ratio of 1 means no difference; 8.74 means far more likely.

Secondary hypogonadism

Low testosterone caused by too little signal from the brain (the pituitary's LH and FSH are low or normal), rather than a problem in the testes themselves (primary hypogonadism).

SERM (selective estrogen receptor modulator)

A tablet, such as clomiphene or enclomiphene, that blocks estrogen's feedback on the brain so it releases more LH and FSH. It is used off-label in men.

SHBG (sex hormone-binding globulin)

A protein made by the liver that carries testosterone in the blood. Obesity and high insulin lower it, which lowers total testosterone even when free testosterone is normal.

Obstructive sleep apnea

Repeated blocking of the airway during sleep, causing pauses in breathing and drops in oxygen. Loud snoring and daytime sleepiness are common signs.

Thrombophilia

An inherited or acquired tendency to form blood clots more easily than normal.

Total testosterone

All the testosterone in a blood sample, bound and free. It is the standard first test for low testosterone.

TRT (testosterone replacement therapy)

Prescribed testosterone, by injection, gel or other forms, for men with low testosterone.

WADA

The World Anti-Doping Agency, which publishes the list of substances banned in sport. Testosterone is prohibited at all times.

How this guide was researched

This guide is built from a thorough review of the sources cited throughout it: clinical guidelines from medical, obesity and surgical societies, product labels, published clinical trials and studies, and regulatory documents. We also reviewed public online forums where men describe their own experiences with weight, low testosterone and treatment.

The guide cites 151 sources, including 72 original studies in people, 19 clinical guidelines and position statements, 9 product labels and 21 public community discussions. Each type of source answers a different question. Guidelines and labels show what clinicians are told to do. Trials and studies show what was measured. Personal accounts show what individual people experienced. Every numbered citation links to its entry below, labeled by source type.

How this guide was made

Research and drafting were AI-assisted. Every cited source was checked against the original, and the guide was reviewed and edited by Doserly before publication. It has not had an independent clinical review, and Doserly does not currently have medical reviewers. Doserly makes a medication and health-tracking app and runs Doserly Academy, both of which are promoted in this guide. Read our editorial policy for how guides are researched, updated and corrected.

This guide is for educational purposes. It summarizes what the reviewed sources report so the research is easier to understand; it is not medical advice. For a deeper dive, or to check any point for yourself, go straight to the cited sources.

Explore the sources